Joshua Jennings
Stock Analyst at TD Cowen
(3.21)
# 987
Out of 5,182 analysts
82
Total ratings
43.59%
Success rate
2.88%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $3.5 → $1 | $0.65 | +53.85% | 4 | Mar 30, 2026 | |
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $4.13 | +45.28% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $23.78 | +42.98% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $62.59 | +59.77% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $240.97 | +3.75% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $81.19 | +19.47% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.24 | +254.19% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $18.17 | +10.07% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $6.69 | +124.22% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $63.21 | +32.89% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.16 | +190.70% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $203.50 | +59.21% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $104.80 | +14.50% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $91.00 | +30.77% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $34.08 | +76.06% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $76.42 | +4.68% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $4.08 | +1,002.94% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $16.65 | +140.24% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $332.30 | +20.37% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $60.33 | -0.55% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $19.17 | +77.36% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.56 | +174.39% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $16.52 | +51.33% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $102.30 | +27.08% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.88 | +165.96% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $86.28 | +35.61% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.97 | +9.39% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $155.32 | +77.05% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $10.10 | +172.28% | 3 | Sep 5, 2018 |
Humacyte
Mar 30, 2026
Maintains: Buy
Price Target: $3.5 → $1
Current: $0.65
Upside: +53.85%
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $4.13
Upside: +45.28%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $23.78
Upside: +42.98%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $62.59
Upside: +59.77%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $240.97
Upside: +3.75%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $81.19
Upside: +19.47%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.24
Upside: +254.19%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $18.17
Upside: +10.07%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $6.69
Upside: +124.22%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $63.21
Upside: +32.89%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.16
Upside: +190.70%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $203.50
Upside: +59.21%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $104.80
Upside: +14.50%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $91.00
Upside: +30.77%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $34.08
Upside: +76.06%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $76.42
Upside: +4.68%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $4.08
Upside: +1,002.94%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $16.65
Upside: +140.24%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $332.30
Upside: +20.37%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $60.33
Upside: -0.55%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $19.17
Upside: +77.36%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.56
Upside: +174.39%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $16.52
Upside: +51.33%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $102.30
Upside: +27.08%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.88
Upside: +165.96%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $86.28
Upside: +35.61%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.97
Upside: +9.39%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $155.32
Upside: +77.05%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $10.10
Upside: +172.28%